Effect of cromolyn on S100P interactions with RAGE and pancreatic cancer growth and invasion in mouse models

Journal of the National Cancer Institute

Volumn 98, Issue 24, 2006, Pages 1806-1818

  Arumugam, Thiruvengadam ^a   Ramachandran, Vijaya ^a   Logsdon, Craig D ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; CROMOGLYCATE DISODIUM; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LUCIFERASE; PROTEIN S 100;

AFFINITY CHROMATOGRAPHY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL ASSAY; CELL INVASION; CELL PROLIFERATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG PROTEIN BINDING; GENE EXPRESSION; IMMUNOPRECIPITATION; MALE; MONOTHERAPY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PANCREAS CANCER; PHOTON; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR BINDING; REPORTER GENE; SINGLE DRUG DOSE; TUMOR GROWTH; WEIGHT REDUCTION;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL LINE, TUMOR; CHROMATOGRAPHY, AFFINITY; CROMOLYN SODIUM; DEOXYCYTIDINE; DRUG SYNERGISM; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; IMMUNOPRECIPITATION; LUCIFERASES; MICE; NEOPLASM INVASIVENESS; NF-KAPPA B; PANCREATIC NEOPLASMS; RECEPTORS, IMMUNOLOGIC; S100 PROTEINS;

EID: 33845906040     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djj498     Document Type: Article

References (37)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26.
2. Maheshwari V, Moser AJ. Current management of locally advanced pancreatic cancer. Nat Clin Pract Gastroenterol Hepatol 2005;2:356-64.
3. Ko AH, Tempero MA. Treatment of metastatic pancreatic cancer. J Natl Compr Canc Netw 2005;3:627-36.
4. Moore MJ, Hamm J, Dancey J, Eisenberg PD, Dagenais M, Fields A, et al. Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003;21:3296-302.
5. Logsdon CD, Simeone DM, Binkley C, Arumugam T, Greenson JK, Giordano TJ, et al. Molecular profi ling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. Cancer Res 2003;63:2649-57.
6. Crnogorac-Jurcevic T, Missiaglia E, Blaveri E, Gangeswaran R, Jones M, Terris B, et al. Molecular alterations in pancreatic carcinoma: expression profiling shows that dysregulated expression of S100 genes is highly prevalent. J Pathol 2003;201:63-74.
7. Sato N, Fukushima N, Matsubayashi H, Goggins M. Identification of maspin and S100P as novel hypomethylation targets in pancreatic cancer using global gene expression profiling. Oncogene 2004;23:1531-8.
8. Wang GZ, Platt-Higgins A, Carroll J, Rudland SD, Winstanley J, Barraclough R, et al. Induction of metastasis by S100P in a rat mammary model and its association with poor survival of breast cancer patients. Cancer Res 2006;66:1199-207.
9. Beer DG, Kardia SL, Huang CC, Giordano TJ, Levin AM, Misek DE, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002;8:816-24.
10. Becker T, Gerke V, Kube E, Weber K. S100P, a novel Ca(2+)-binding protein from human placenta. cDNA cloning, recombinant protein expression and Ca2+ binding properties. Eur J Biochem 1992;207:541-7.
11. Arumugam T, Simeone DM, Van Golen K, Logsdon CD. S100P promotes pancreatic cancer growth, survival, and invasion. Clin Cancer Res 2005;11:5356-64.
12. Bertram J, Palfner K, Hiddemann W, Kneba M. Elevated expression of S100P, CAPL and MAGE 3 in doxorubicin-resistant cell lines: Comparison of mRNA differential display reverse transcription-polymerase chain reaction and subtractive suppressive hybridization for the analysis of differential gene expression. Anticancer Drugs 1998;9:311-7.
13. Arumugam T, Simeone DM, Schmidt AM, Logsdon CD. S100P stimulates cell proliferation and survival via receptor for activated glycation end products (RAGE). J Biol Chem 2004;279:5059-65.
14. Stern D, Du YS, Fang YS, Marie SA. Receptor for advanced glycation end-products: A multiligand receptor magnifying cell stress in diverse pathologic settings. Adv Drug Deliv Rev 2002;54:1615-25.
15. Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ. The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 1999;5:119-27.
16. Karin M, Cao Y, Greten FR, Li ZW. NF-kappaB in cancer: From innocent bystander to major culprit. Nat Rev Cancer 2002;2:301-10.
17. Arlt A, Vorndamm J, Breitenbroich M, Folsch UR, Kalthoff H, Schmidt WE, et al. Inhibition of NF-kappaB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide VP16 or doxorubicin. Oncogene 2001;20:859-68.
18. Storms W, Kaliner MA. Cromolyn sodium: Fi tting an old friend into current asthma treatment. J Asthma 2005;42:79-89.
19. Oyama Y, Shishibori T, Yamashita K, Naya T, Nakagiri S, Maeta H, et al. Two distinct anti-allergic drugs, amlexanox and cromolyn, bind to the same kinds of calcium binding proteins, except calmodulin, in bovine lung extract. Biochem Biophys Res Commun 1997;240:341-7.
20. Okada M, Tokumitsu H, Kubota Y, Kobayashi R. Interaction of S100 proteins with the antiallergic drugs, olopatadine, amlexanox, and cromolyn: Identifi cation of putative drug binding sites on S100A1 protein. Biochem Biophys Res Commun 2002;292:1023-30.
21. Shishibori T, Oyama Y, Matsushita O, Yamashita K, Furuichi H, Okabe A, et al. Three distinct anti-allergic drugs, amlexanox, cromolyn and tranilast, bind to S100A12 and S100A13 of the S100 protein family. Biochem J 1999;338:583-9.
22. Peiper M, Nagoshi M, Patel D, Fletcher JA, Goegebuure PS, Eberlein TJ. Human pancreatic cancer cells MPanc-96 recognized by autologous tumor-infiltrating lymphocytes after in vitro as well as in vivo tumor expansion. Int J Cancer 1997; 71: 993-9.
23. Qin XF, An DS, Chen IS, Baltimore D. Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci U S A 2003;100:183-8.
24. Mazurek N, Schindler H, Schurholz T, Pecht I. The cromolyn binding protein constitutes the Ca2+ channel of basophils opening upon immunological stimulus. Proc Natl Acad Sci U S A 1984;81:6841-5.
25. Cox A, Law NM, Findlay JB. Inhibition of cromolyn-induced phosphorylation of a 78-kDa protein by phorbol esters in rat peritoneal mast cells. Biochem Pharmacol 1998;55:585-94.
26. Garland LG, Mongar JL. Inhibition by cromoglycate of histamine release from rat peritoneal mast cells induced by mixtures of dextran, phosphatidyl serine and calcium ions. Br J Pharmacol 1974;50:137-43.
27. White JR, Pearce FL. Effect of anti-allergic compounds on anaphylactic histamine secretion from rat peritoneal mast cells in the presence and absence of exogenous calcium. Immunology 1982;46:361-7.
28. Holian A, Hamilton R, Scheule RK. Mechanistic aspects of cromolyn sodium action on the alveolar macrophage: Inhibition of stimulation by soluble agonists. Agents Actions 1991;33:318-25.
29. Correia I, Wang L, Pang X, Theoharides TC. Characterization of the 78 kDa mast cell protein phosphorylated by the antiallergic drug cromolyn and homology to moesin. Biochem Pharmacol 1996;52:413-24.
30. Reinsprecht M, Pecht I, Schindler H, Romanin C. Potent block of Cl-channels by antiallergic drugs. Biochem Biophys Res Commun 1992;188:957-63.
31. Lucas AM, Shuster S. Cromolyn inhibition of protein kinase C activity. Biochem Pharmacol 1987;36:562-5.
32. Hemmerich S, Yarden Y, Pecht I. A cromoglycate binding protein from rat mast cells of a leukemia line is a nucleoside diphosphate kinase. Biochemistry 1992;31:4574-9.
33. Samoszuk M, Corwin MA. Mast cell inhibitor cromolyn increases blood clotting and hypoxia in murine breast cancer. Int J Cancer 2003;107: 159-63.
34. Ionov ID. Inhibition of mast-cell activity as a new approach to anticancer therapy. Int J Radiat Biol 1991;60:287-91.
35. Donato R. Intracellular and extracellular roles of S100 proteins. Microsc Res Tech 2003;60:540-51.
36. Averboukh L, Liang P, Kantoff PW, Pardee AB. Regulation of S100P expression by androgen. Prostate 1996;29:350-5.
37. Crnogorac-Jurcevic T, Efthimiou E, Nielsen T, Loader J, Terris B, Stamp G, et al. Expression profi ling of microdissected pancreatic adenocarcinomas. Oncogene 2002;21:4587-94.